Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,838
datasets available to search
ShareScore release 0.9.0
Dataset results
1,838 results for “Endometrial”
ZW25 in Women With Endometrial Cancers
ClinicalTrials.gov study NCT04513665. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: Endometrial decidualization status modulates endometrial microvascular complexity and trophoblast outgrowth in gelatin methacryloyl hydrogels
Open the record for dataset details and reuse information.
Human seminal extracellular vesicles enhance endometrial receptivity through leukemia inhibitory factor
<p>Seminal extracellular vesicles (EVs) contain different subgroups that have diverse effects on sperm function. However, the effect of seminal EVs—especially its subgroups, on the endometrial receptivity was largely unknown. Here, we found that the seminal EVs could be divided into high-density EV (EV-H), medium density EV (EV-M), and low-density EV (EV-L), after purification using iodixanol. Then we demonstrated that EV-H could promote the expression and secretion of leukemia inhibitor factor (LIF) in human endometrial cells. In EV-H-treated endometrial cells, we identified 1274 differentially expressed genes (DEGs). DEGs were enriched in cell adhesion and AKT, STAT3 pathways. Therefore, we illustrated that EV-H enhanced the adhesion of human choriocarcinoma JAr cell spheroids to endometrial cells through the LIF-STAT3 pathway. Collectively, our findings indicated that seminal EV-H could regulate endometrial receptivity through the LIF pathway, which would provide novel insights into male fertility.</p>
Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma
<p>Responses to immune checkpoint blockade (ICB) are variable even among mismatch repair deficient (MMRd) cancers. We completed a phase 2 clinical trial of the PD-1 inhibitor pembrolizumab in 24 patients with MMRd endometrial cancer (NCT02899793). Patients with mutational MMRd tumors (6 patients) had higher response rates and longer survival than those with epigenetic MMRd tumors (18 patients). Mutation burden was higher in tumors with mutational MMRd compared to epigenetic MMRd; however, within each category of MMRd, mutation burden was not associated with ICB response. Notably, JAK1 mutations did not confer resistance to pembrolizumab. Longitudinal single-cell RNA-seq of circulating immune cells revealed contrasting modes of anti-tumor immunity against mutational and epigenetic MMRd tumors. Whereas effector CD8+ T cell responses correlated with mutational MMRd, highly active CD16+ NK cells were associated with epigenetic MMRd tumors responsive to ICB. These data highlight factors beyond neoantigen burden that influence ICB response.</p>
H&E cervix & endometrial plasma cell nuclei dataset
<p>H&E plasma cell nuclei dataset (from cervix & endometrial tissues, plasma cell/other, 224x224 pixels at 40x magnification)</p> <p>This description will be updated soon...</p>
Endometrial Cancer (All histologies) bGWAS results
<p>Output from multi-trait GWAS analysis of endometrial cancer and risk factors using bGWAS software. This includes results from Bayes Factor analysis, and assessment of posterior and direct effects.</p>
Proteomic characterization of intra-tumor heterogeneity in human endometrial cancer.
<p>Endometrial cancer (EC) is one of the most frequently diagnosed gynecological cancers worldwide, and its prevalence has increased by more than 50% over the last two decades. Despite the understanding of the major signaling pathways driving the growth and metastasis of EC cells, clinical trials targeting these signaling pathways in human patients have reported poor outcomes. Heterogeneous nature of EC is suspected to be one of the key reasons for the failure of targeted therapies. However, no study so far has explored EC heterogeneity within the same patient at the proteomic level. In this study, we isolated proteins from tumor tissue samples obtained from different sites of EC from individual patients (~2-4 samples/patient). We then performed a SWATH-based comparative proteomic analysis, using liquid chromatography-tandem mass spectrometry (LC-MS/MS), to profile the protein content of different areas within EC tissue. Our results highlighted an average of 1424 unique proteins in 20 patient-derived EC tissues with a confidence corresponding to a false discovery rate below 1%. We have identified protein biomarkers that differentiate between premenopausal vs postmenopausal cancer, macroscopic vs microscopic tumor, more vs less invasive cancer, and DNA mismatch repair defective vs intact tumor. Furthermore, the data revealed a list of unique proteins that, for the same patient, exist only in a single EC location but are not present in other locations within the same tumor. Overall, our proteomic analysis highlighted that tumor tissue samples collected from different sites of EC within the same patient can harbor diverse protein profiles. Importantly, this study sets the foundation for further investigations into the mechanisms of endometrial heterogeneity and some of the proteins identified here may represent potential novel EC drug targets.</p>
Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility
<p>Full results datasets for Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility:</p> <p>ALL*all_pheno.csv are TOPMed-MESA combined-ancestry models, discovery and replication cohorts</p> <p>ARIC_EA_all_pheno.csv is ARIC European-American ancestry models, discovery cohort</p> <p>ARIC*meta_all.txt is ARIC European-American ancestry models, discovery and replication cohorts, with meta-analysis of disc+rep</p>
Endometrial Safety Study
ClinicalTrials.gov study NCT00522873. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
ClinicalTrials.gov study NCT04291612. IPD Sharing: YES. Countries: 4. Publications: 1.
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
ClinicalTrials.gov study NCT03394027. IPD Sharing: YES. Countries: 1. Publications: 4.
Endometrial Injury for Assisted Reproduction
ClinicalTrials.gov study NCT01132144. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
ClinicalTrials.gov study NCT05255653. IPD Sharing: YES. Countries: 4. Publications: 2.
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
ClinicalTrials.gov study NCT00808132. IPD Sharing: Not stated. Countries: 12. Publications: 2.
Decreasing Postoperative Pain Following Endometrial Ablation
ClinicalTrials.gov study NCT02660918. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
ClinicalTrials.gov study NCT03015129. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Real-time Lymphatic Channel Visualization Improves Bilateral Sentinel Lymph Node Detection in Endometrial Cancer
ClinicalTrials.gov study NCT05191212. IPD Sharing: NO. Countries: 1. Publications: 3.
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
ClinicalTrials.gov study NCT01068249. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
ClinicalTrials.gov study NCT01005329. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
ClinicalTrials.gov study NCT01165307. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.